Direkt zum Inhalt
Merck

MAB8257B

Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated

clone A1, Chemicon®, from mouse

Slide 1 of 1
Anmelden Preise für Organisationen und Verträge anzeigen

Größe auswählen

100 μG

CHF 742.00

CHF 742.00

Warenkorb auf Verfügbarkeit prüfen
Fordern Sie eine Massenbestellung an

Über diesen Artikel

UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Biologische Quelle

mouse

Qualitätsniveau

300

Konjugat

biotin conjugate

Antikörperform

purified immunoglobulin

Antikörper-Produkttyp

primary antibodies

Klon

A1, monoclonal

Speziesreaktivität

human

Hersteller/Markenname

Chemicon®

Methode(n)

immunofluorescence: suitable

Isotyp

IgG2a

Versandbedingung

wet ice

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
MAB8257MAB8257FMAB8251
Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated clone A1, Chemicon®, from mouse

Sigma-Aldrich

MAB8257B

Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated

Anti-Influenza-A-Antikörper, Nukleoprotein, Klon A1 clone A1, Chemicon®, from mouse

Sigma-Aldrich

MAB8257

Anti-Influenza-A-Antikörper, Nukleoprotein, Klon A1

Anti-Influenza-A-Antikörper (Nukleoprotein, Klon A1, FITC-konjugiert) clone A1, Chemicon®, from mouse

Sigma-Aldrich

MAB8257F

Anti-Influenza-A-Antikörper (Nukleoprotein, Klon A1, FITC-konjugiert)

Anti-Influenza A-Antikörper, Nukleoprotein, Klone A1, A3, Mischung ascites fluid, Chemicon®, from mouse

Sigma-Aldrich

MAB8251

Anti-Influenza A-Antikörper, Nukleoprotein, Klone A1, A3, Mischung

biological source

mouse

biological source

mouse

biological source

mouse

biological source

mouse

antibody form

purified immunoglobulin

antibody form

purified immunoglobulin

antibody form

purified antibody

antibody form

ascites fluid

clone

A1, monoclonal

clone

A1, monoclonal

clone

A1, monoclonal

clone

A1, monoclonal, A3, monoclonal

species reactivity

human

species reactivity

human

species reactivity

human

species reactivity

human

conjugate

biotin conjugate

conjugate

-

conjugate

FITC conjugate

conjugate

-

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

technique(s)

immunofluorescence: suitable

Immunogen

Epitope: nucleoprotein
Influenza A

Anwendung

Research Category
Infektionskrankheiten
Research Sub Category
Virale Infektionskrankheiten
Detect Influenza A using this Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated validated for use in IF.
Immunofluorescence

Optimal dilutions must be determined by end user.

Biochem./physiol. Wirkung

Specific for the Influenza A nucleoprotein. Has stronger binding with N1-type Flu A. Has been shown to react with the H5N1 strain. No cross reactivity seen to influenza B or other respiratory viruses.

Physikalische Form

Biotin conjugated purified immunoglobulin. Liquid in 0.01M PBS, pH=7.1, 0.1% Sodium Azide with 15 mg/mL BSA as stabilizer.

Angaben zur Herstellung

Maintain at 2 to 8°C for up to 12 months from date of receipt. Protect from Light.

Sonstige Hinweise

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Rechtliche Hinweise

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Roozbeh Abedini-Nassab et al.
Micromachines, 12(7) (2021-07-03)
Magnetic nanoparticles have attracted significant attention in various disciplines, including engineering and medicine. Microfluidic chips and lab-on-a-chip devices, with precise control over small volumes of fluids and tiny particles, are appropriate tools for the synthesis, manipulation, and evaluation of nanoparticles.
Sergey Yegorov et al.
Cell reports. Medicine, 3(2), 100509-100509 (2022-03-05)
The induction of broadly neutralizing antibodies (bNAbs) that target the hemagglutinin stalk domain is a promising strategy for the development of "universal" influenza virus vaccines. bNAbs can be boosted in adults by sequential exposure to heterosubtypic viruses through natural infection
Felix Broecker et al.
NPJ vaccines, 4, 31-31 (2019-07-26)
Current seasonal influenza virus vaccines only provide limited, short-lived protection, and antigenic drift in the hemagglutinin surface glycoprotein necessitates their annual re-formulation and re-administration. To overcome these limitations, universal vaccine strategies that aim at eliciting broadly protective antibodies to conserved
Erin E H Tran et al.
mBio, 7(2), e00257-e00257 (2016-03-24)
Influenza viruses expressing chimeric hemagglutinins (HAs) are important tools in the quest for a universal vaccine. Using cryo-electron tomography, we have determined the structures of a chimeric HA variant that comprises an H1 stalk and an H5 globular head domain
David J Holthausen et al.
Immunity, 46(4), 587-595 (2017-04-20)
Although vaccines confer protection against influenza A viruses, antiviral treatment becomes the first line of defense during pandemics because there is insufficient time to produce vaccines. Current antiviral drugs are susceptible to drug resistance, and developing new antivirals is essential.
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung